Physician profile
Trusha Patel
NPI 1972943512
$617.62
in general payments reported to CMS, 2019-2025
11 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $72.94 · 2021: $106 · 2022: $26.07 · 2024: $83.32 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $213.03 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $103.31 | 2024-2025 | Miebo |
| Harrow Eye, LLC | $72.61 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $58.33 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $37.61 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $32.67 | 2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $23.82 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $22.00 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.39 | 2019 | |
| Alcon Vision LLC | $17.96 | 2025 | Rocklatan |
| Allergan, INC. | $16.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trusha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.